Search

Your search keyword '"Freeman, Leorah"' showing total 10 results
Start Over Author "Freeman, Leorah" Database OAIster
10 results on '"Freeman, Leorah"'

1. A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis.

Author

Daboul, Lynn, Daboul, Lynn, ODonnell, Carly, Amin, Moein, Rodrigues, Paulo, Derbyshire, John, Azevedo, Christina, Bar-Or, Amit, Caverzasi, Eduardo, Calabresi, Peter, Freeman, Leorah, Henry, Roland, Longbrake, Erin, Oh, Jiwon, Papinutto, Nico, Pelletier, Daniel, Prchkovska, Vesna, Raza, Praneeta, Ramos, Marc, Samudralwar, Rohini, Schindler, Matthew, Sotirchos, Elias, Sicotte, Nancy, Solomon, Andrew, Shinohara, Russell, Reich, Daniel, Sati, Pascal, Ontaneda, Daniel, Cree, Bruce, Daboul, Lynn, Daboul, Lynn, ODonnell, Carly, Amin, Moein, Rodrigues, Paulo, Derbyshire, John, Azevedo, Christina, Bar-Or, Amit, Caverzasi, Eduardo, Calabresi, Peter, Freeman, Leorah, Henry, Roland, Longbrake, Erin, Oh, Jiwon, Papinutto, Nico, Pelletier, Daniel, Prchkovska, Vesna, Raza, Praneeta, Ramos, Marc, Samudralwar, Rohini, Schindler, Matthew, Sotirchos, Elias, Sicotte, Nancy, Solomon, Andrew, Shinohara, Russell, Reich, Daniel, Sati, Pascal, Ontaneda, Daniel, and Cree, Bruce

Abstract

BACKGROUND: The central vein sign (CVS) is a proposed magnetic resonance imaging (MRI) biomarker for multiple sclerosis (MS); the optimal method for abbreviated CVS scoring is not yet established. OBJECTIVE: The aim of this study was to evaluate the performance of a simplified approach to CVS assessment in a multicenter study of patients being evaluated for suspected MS. METHODS: Adults referred for possible MS to 10 sites were recruited. A post-Gd 3D T2*-weighted MRI sequence (FLAIR*) was obtained in each subject. Trained raters at each site identified up to six CVS-positive lesions per FLAIR* scan. Diagnostic performance of CVS was evaluated for a diagnosis of MS which had been confirmed using the 2017 McDonald criteria at thresholds including three positive lesions (Select-3*) and six positive lesions (Select-6*). Inter-rater reliability assessments were performed. RESULTS: Overall, 78 participants were analyzed; 37 (47%) were diagnosed with MS, and 41 (53%) were not. The mean age of participants was 45 (range: 19-64) years, and most were female (n = 55, 71%). The area under the receiver operating characteristic curve (AUROC) for the simplified counting method was 0.83 (95% CI: 0.73-0.93). Select-3* and Select-6* had sensitivity of 81% and 65% and specificity of 68% and 98%, respectively. Inter-rater agreement was 78% for Select-3* and 83% for Select-6*. CONCLUSION: A simplified method for CVS assessment in patients referred for suspected MS demonstrated good diagnostic performance and inter-rater agreement.

Published
2024

2. Choroid plexus volume differentiates MS from its mimics.

Author

Levit, Elle, Levit, Elle, Ren, Zheng, Gonzenbach, Virgilio, Azevedo, Christina, Calabresi, Peter, Cree, Bruce, Freeman, Leorah, Longbrake, Erin, Oh, Jiwon, Schindler, Matthew, Sicotte, Nancy, Reich, Daniel, Ontaneda, Daniel, Sati, Pascal, Cao, Quy, Shinohara, Russell, Solomon, Andrew, Levit, Elle, Levit, Elle, Ren, Zheng, Gonzenbach, Virgilio, Azevedo, Christina, Calabresi, Peter, Cree, Bruce, Freeman, Leorah, Longbrake, Erin, Oh, Jiwon, Schindler, Matthew, Sicotte, Nancy, Reich, Daniel, Ontaneda, Daniel, Sati, Pascal, Cao, Quy, Shinohara, Russell, and Solomon, Andrew

Abstract

This study aimed to determine whether choroid plexus volume (CPV) could differentiate multiple sclerosis (MS) from its mimics. A secondary analysis of two previously enrolled studies, 50 participants with MS and 64 with alternative diagnoses were included. CPV was automatically segmented from 3T magnetic resonance imaging (MRI), followed by manual review to remove misclassified tissue. Mean normalized choroid plexus volume (nCPV) to intracranial volume demonstrated relatively high specificity for MS participants in each cohort (0.80 and 0.76) with an area under the receiver-operator characteristic curve of 0.71 (95% confidence interval (CI) = 0.55-0.87) and 0.65 (95% CI = 0.52-0.77). In this preliminary study, nCPV differentiated MS from its mimics.

Published
2024

3. Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients

Author

Freeman,Leorah, Kee,Arianna, Tian,Marc, Mehta,Rina, Freeman,Leorah, Kee,Arianna, Tian,Marc, and Mehta,Rina

Abstract

Leorah Freeman,1 Arianna Kee,2 Marc Tian,2 Rina Mehta2 1Dell Medical School, The University of Texas at Austin, TX, USA; 2Bristol Myers Squibb, Princeton, NJ, USACorrespondence: Leorah FreemanHealth Discovery Building, Dell Medical School, The University of Texas at Austin, 1601 Trinity Street, Austin, TX 78701, USATel + 1-512-495-5355Email leorah.freeman@austin.utexas.eduPurpose: Early diagnosis and treatment of multiple sclerosis (MS) with disease-modifying therapy (DMT) can reduce relapse number and severity, which has cost implications. We describe treatment patterns, healthcare utilization, and cost among MS patients newly initiating DMTs (index).Patients and Methods: DMT-naïve adults with 12 months’ continuous enrollment pre- and post-index and ≥ 2 MS claims (2009‒2018) were identified from the Optum Clinformatics Data Mart database. Treatment adherence and persistence were measured as time on index DMT. Relapses were identified using a validated claims-based algorithm. All-cause and MS-related healthcare expenditures and utilization were captured pre- and post-index. Outcomes were stratified by route of administration. Multivariate analyses assessed differences in outcomes and costs.Results: The analysis included 5906 MS patients (mean age, 46.6 years). The majority initiated injectable (63.5%) followed by oral (28.8%) and infusion (7.7%) DMTs. Post-index, 45.3% of patients were nonadherent and 39.4% were nonpersistent. Relapse rates decreased from pre- to post-index (oral: 24.3%‒16.1%; injectable: 25.0%‒17.1%; infusion: 29.3%‒15.5%). Post-index mean (SD) all-cause total costs were lowest with oral ($70,970 [$36,681]) vs injectable ($82,521 [$58,569]) and infusion ($80,871 [$49,627]) DMTs. MS-related total costs were lowest with oral ($65,149 [$65,133]) vs injectable ($76,197 [$60,204]) and infusion ($72,703 [$47,287]) DMTs. Multivariate analysis showed no differences between oral and injectable DMTs in adherence, persistence

Published
2021

4. A young man in 'double-trouble': Hallucinations and cranial nerve palsies: From the National Multiple Sclerosis Society Case Conference Proceedings.

Author

Bradshaw, Michael J, Bradshaw, Michael J, Lisak, Robert P, Meltzer, Ethan, Melamed, Esther, Lucas, Ashlea, Freeman, Leorah, Frohman, Teresa C, Costello, Kathleen, Balcer, Laura, Galetta, Steven, Chitnis, Tanuja, Zamvil, Scott S, Frohman, Elliot M, Bradshaw, Michael J, Bradshaw, Michael J, Lisak, Robert P, Meltzer, Ethan, Melamed, Esther, Lucas, Ashlea, Freeman, Leorah, Frohman, Teresa C, Costello, Kathleen, Balcer, Laura, Galetta, Steven, Chitnis, Tanuja, Zamvil, Scott S, and Frohman, Elliot M

Published
2019

5. Cataclysmically disseminating neurologic presentation in an immunosuppressed lupus patient: From the National Multiple Sclerosis Society Case Conference Proceedings.

Author

Perrone, Christopher M, Perrone, Christopher M, Lisak, Robert P, Meltzer, Ethan I, Sguigna, Peter, Tizazu, Etsegenet, Jacobs, Dina, Melamed, Esther, Lucas, Ashlea, Freeman, Leorah, Pardo, Gabriel, Goodman, Andrew, Fox, Edward J, Costello, Kathleen, Parsons, Matthew S, Zamvil, Scott S, Frohman, Elliot M, Frohman, Teresa C, Perrone, Christopher M, Perrone, Christopher M, Lisak, Robert P, Meltzer, Ethan I, Sguigna, Peter, Tizazu, Etsegenet, Jacobs, Dina, Melamed, Esther, Lucas, Ashlea, Freeman, Leorah, Pardo, Gabriel, Goodman, Andrew, Fox, Edward J, Costello, Kathleen, Parsons, Matthew S, Zamvil, Scott S, Frohman, Elliot M, and Frohman, Teresa C

Published
2019

6. A young man in 'double-trouble': Hallucinations and cranial nerve palsies: From the National Multiple Sclerosis Society Case Conference Proceedings.

Author

Bradshaw, Michael J, Bradshaw, Michael J, Lisak, Robert P, Meltzer, Ethan, Melamed, Esther, Lucas, Ashlea, Freeman, Leorah, Frohman, Teresa C, Costello, Kathleen, Balcer, Laura, Galetta, Steven, Chitnis, Tanuja, Zamvil, Scott S, Frohman, Elliot M, Bradshaw, Michael J, Bradshaw, Michael J, Lisak, Robert P, Meltzer, Ethan, Melamed, Esther, Lucas, Ashlea, Freeman, Leorah, Frohman, Teresa C, Costello, Kathleen, Balcer, Laura, Galetta, Steven, Chitnis, Tanuja, Zamvil, Scott S, and Frohman, Elliot M

Published
2019

7. Cataclysmically disseminating neurologic presentation in an immunosuppressed lupus patient: From the National Multiple Sclerosis Society Case Conference Proceedings.

Author

Perrone, Christopher M, Perrone, Christopher M, Lisak, Robert P, Meltzer, Ethan I, Sguigna, Peter, Tizazu, Etsegenet, Jacobs, Dina, Melamed, Esther, Lucas, Ashlea, Freeman, Leorah, Pardo, Gabriel, Goodman, Andrew, Fox, Edward J, Costello, Kathleen, Parsons, Matthew S, Zamvil, Scott S, Frohman, Elliot M, Frohman, Teresa C, Perrone, Christopher M, Perrone, Christopher M, Lisak, Robert P, Meltzer, Ethan I, Sguigna, Peter, Tizazu, Etsegenet, Jacobs, Dina, Melamed, Esther, Lucas, Ashlea, Freeman, Leorah, Pardo, Gabriel, Goodman, Andrew, Fox, Edward J, Costello, Kathleen, Parsons, Matthew S, Zamvil, Scott S, Frohman, Elliot M, and Frohman, Teresa C

Published
2019

8. Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMS.

Author

Oh, Jiwon, Oh, Jiwon, Ontaneda, Daniel, Azevedo, Christina, Klawiter, Eric C, Absinta, Martina, Arnold, Douglas L, Bakshi, Rohit, Calabresi, Peter A, Crainiceanu, Ciprian, Dewey, Blake, Freeman, Leorah, Gauthier, Susan, Henry, Roland, Inglese, Mathilde, Kolind, Shannon, Li, David KB, Mainero, Caterina, Menon, Ravi S, Nair, Govind, Narayanan, Sridar, Nelson, Flavia, Pelletier, Daniel, Rauscher, Alexander, Rooney, William, Sati, Pascal, Schwartz, Daniel, Shinohara, Russell T, Tagge, Ian, Traboulsee, Anthony, Wang, Yi, Yoo, Youngjin, Yousry, Tarek, Zhang, Yunyan, Sicotte, Nancy L, Reich, Daniel S, North American Imaging in Multiple Sclerosis Cooperative, Oh, Jiwon, Oh, Jiwon, Ontaneda, Daniel, Azevedo, Christina, Klawiter, Eric C, Absinta, Martina, Arnold, Douglas L, Bakshi, Rohit, Calabresi, Peter A, Crainiceanu, Ciprian, Dewey, Blake, Freeman, Leorah, Gauthier, Susan, Henry, Roland, Inglese, Mathilde, Kolind, Shannon, Li, David KB, Mainero, Caterina, Menon, Ravi S, Nair, Govind, Narayanan, Sridar, Nelson, Flavia, Pelletier, Daniel, Rauscher, Alexander, Rooney, William, Sati, Pascal, Schwartz, Daniel, Shinohara, Russell T, Tagge, Ian, Traboulsee, Anthony, Wang, Yi, Yoo, Youngjin, Yousry, Tarek, Zhang, Yunyan, Sicotte, Nancy L, Reich, Daniel S, and North American Imaging in Multiple Sclerosis Cooperative

Abstract

ObjectiveTo summarize current and emerging imaging techniques that can be used to assess neuroprotection and repair in multiple sclerosis (MS), and to provide a consensus opinion on the potential utility of each technique in clinical trial settings.MethodsClinicians and scientists with expertise in the use of MRI in MS convened in Toronto, Canada, in November 2016 at a North American Imaging in Multiple Sclerosis (NAIMS) Cooperative workshop meeting. The discussion was compiled into a manuscript and circulated to all NAIMS members in attendance. Edits and feedback were incorporated until all authors were in agreement.ResultsA wide spectrum of imaging techniques and analysis methods in the context of specific study designs were discussed, with a focus on the utility and limitations of applying each technique to assess neuroprotection and repair. Techniques were discussed under specific themes, and included conventional imaging, magnetization transfer ratio, diffusion tensor imaging, susceptibility-weighted imaging, imaging cortical lesions, magnetic resonance spectroscopy, PET, advanced diffusion imaging, sodium imaging, multimodal techniques, imaging of special regions, statistical considerations, and study design.ConclusionsImaging biomarkers of neuroprotection and repair are an unmet need in MS. There are a number of promising techniques with different strengths and limitations, and selection of a specific technique will depend on a number of factors, notably the question the trial seeks to answer. Ongoing collaborative efforts will enable further refinement and improved methods to image the effect of novel therapeutic agents that exert benefit in MS predominately through neuroprotective and reparative mechanisms.

Published
2019

9. A young man with numbness in arms and legs: From the National Multiple Sclerosis Society Case Conference Proceedings.

Author

Romeo, Andrew R, Romeo, Andrew R, Lisak, Robert P, Meltzer, Ethan, Fox, Edward J, Melamed, Esther, Lucas, Ashlea, Freeman, Leorah, Frohman, Teresa C, Costello, Kathleen, Zamvil, Scott S, Frohman, Elliot M, Gelfand, Jeffrey M, Romeo, Andrew R, Romeo, Andrew R, Lisak, Robert P, Meltzer, Ethan, Fox, Edward J, Melamed, Esther, Lucas, Ashlea, Freeman, Leorah, Frohman, Teresa C, Costello, Kathleen, Zamvil, Scott S, Frohman, Elliot M, and Gelfand, Jeffrey M

Published
2018

10. A young man with numbness in arms and legs: From the National Multiple Sclerosis Society Case Conference Proceedings.

Author

Romeo, Andrew R, Romeo, Andrew R, Lisak, Robert P, Meltzer, Ethan, Fox, Edward J, Melamed, Esther, Lucas, Ashlea, Freeman, Leorah, Frohman, Teresa C, Costello, Kathleen, Zamvil, Scott S, Frohman, Elliot M, Gelfand, Jeffrey M, Romeo, Andrew R, Romeo, Andrew R, Lisak, Robert P, Meltzer, Ethan, Fox, Edward J, Melamed, Esther, Lucas, Ashlea, Freeman, Leorah, Frohman, Teresa C, Costello, Kathleen, Zamvil, Scott S, Frohman, Elliot M, and Gelfand, Jeffrey M

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results